



Published in final edited form as:

*Gastroenterology*. 2011 December ; 141(6): 2109–2118. doi:10.1053/j.gastro.2011.09.015.

## Gut-tropic T Cells that Express Integrin $\alpha 4\beta 7$ and CCR9 are Required for Induction of Oral Immune Tolerance in Mice

Barbara Cassani<sup>1,\*</sup>, Eduardo J. Villablanca<sup>1,\*</sup>, Francisco J. Quintana<sup>2</sup>, Paul E. Love<sup>3</sup>, Adam Lacy-Hulbert<sup>4</sup>, William S. Blaner<sup>5</sup>, Tim Sparwasser<sup>6</sup>, Scott B. Snapper<sup>7</sup>, Howard L. Weiner<sup>2</sup>, and J. Rodrigo Mora<sup>1,\*\*</sup>

<sup>1</sup>Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114

<sup>2</sup>Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115

<sup>3</sup>Eunice Kennedy Schriver, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892

<sup>4</sup>Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114

<sup>5</sup>Department of Medicine, Columbia University, New York, NY 10032

<sup>6</sup>Institute of Infection Immunology, Centre for Experimental and Clinical Infection Research, Twincore, 30625 Hannover, Germany

<sup>7</sup>Gastrointestinal Unit, Children's Hospital & Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115

### Abstract

**BACKGROUND & AIMS**—Induction of oral immunological tolerance (OT) blocks proinflammatory responses to orally administered antigens; this approach might be used to treat autoimmune conditions. We investigated whether gut-tropic T cells that express the integrin  $\alpha 4\beta 7$  and the chemokine receptor CCR9 are required for OT.

**METHODS**—Skin delayed-type hypersensitivity and experimental autoimmune encephalomyelitis were used to monitor OT in mice. To assess the role of receptors that mediate localization of lymphocytes to the gut (gut-homing receptors) in induction of OT, we studied *CCR9*<sup>-/-</sup> and  *$\beta 7$* <sup>-/-</sup> mice, and also blocked the  $\alpha 4\beta 7$  ligand MAdCAM-1 in wild-type mice. We

© 2011 The American Gastroenterological Association. Published by Elsevier Inc. All rights reserved

\*\*Correspondence and requests for materials should be addressed to J. Rodrigo Mora (j\_rodrigo\_mora@hms.harvard.edu).

\*BC and EJV contributed equally to this work

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Author's Contributions:** BC and EJV designed and performed most of the experiments, analyzed the data and wrote the paper. PEL provided *CCR9*<sup>-/-</sup> mice. FJQ and HLW performed the experiments and analyzed the data in the EAE model. ALH helped designing some experiments. WSB provided *LRAT*<sup>-/-</sup> mice. TS provided *DEREG* mice. SBS provided *IL-10R $\beta$* <sup>-/-</sup> mice and helped designing some experiments. JRM conceived the study, designed experiments, analyzed the data and wrote the paper. All authors read and approved the final manuscript.

**Conflicts of interest:** The authors declare no competing financial interests.

**Online Supplemental Material:** Supplementary Figures S1–S10 plus supplementary methods.

used DEREg and Scurfy mice to assess the role of Foxp3<sup>+</sup> regulatory T (T<sub>REG</sub>) cells, and *IL-10*<sup>-/-</sup> and *IL-10Rβ*<sup>-/-</sup> mice to examine the role of IL-10, in induction of OT.

**RESULTS**—OT could not be induced in *CCR9*<sup>-/-</sup> or *β7*<sup>-/-</sup> mice, or when MAdCAM-1 was blocked in wild-type mice, indicating that gut-homing receptors are required for oral tolerization. Consistent with the role of all-trans retinoic acid in inducing gut homing T cells, OT could not be induced in mice depleted of vitamin A. OT was rescued in *CCR9*<sup>-/-</sup> mice following adoptive transfer of wild-type T cells, but not *CCR9*<sup>-/-</sup> or *β7*<sup>-/-</sup> T cells. Gut-homing T cells are therefore necessary and sufficient to induce OT. Wild-type T<sub>REG</sub> cells and IL-10 were required to restore OT to *CCR9*<sup>-/-</sup> mice, indicating that homing and functional differentiation of IL-10-producing T<sub>REG</sub> cells in the gut is required for OT. Conversely, transfer of *CCR9*<sup>-/-</sup> or *β7*<sup>-/-</sup> T cells to wild-type mice partially inhibited OT.

**CONCLUSIONS**—Expression of CCR9 and α4β7 on T cells and their subsequent localization to the gut is required for induction of oral immunological tolerance in mice. Therapies designed to block gut-homing receptors might, under some conditions, interfere with normal tolerogenic mechanisms in the intestinal mucosa.

## Keywords

immune regulation; autoimmunity; allergy; intestine; Peyer's patch

Two general mechanisms have been proposed to induce OT. Feeding high doses of antigen typically results in T cell clonal deletion and/or anergy<sup>1</sup>, while low doses/repeating regimes of oral antigen administration lead to active immunosuppression by inducing regulatory T cells<sup>2, 3</sup>. Although orally administered antigens can be presented to T cells by dendritic cells (DC) in Peyer's patches (PP) and mesenteric lymph nodes (MLN), it has been shown that OT requires MLN<sup>4, 5</sup> but not PP<sup>4</sup>. In this setting, orally administered antigens are captured by DC in the intestinal lamina propria (LP) and transported to MLN via the lymph. DC from MLN, PP and small intestine lamina propria (gut-associated DC) induce high expression of gut-homing receptors integrin α4β7 and chemokine receptor CCR9 on lymphocytes upon activation<sup>6</sup>. The capacity of gut-associated DC to imprint gut-tropism on lymphocytes is explained by their selective capacity to metabolize vitamin A into RA<sup>7</sup>, and RA is necessary and sufficient to induce gut-tropic α4β7<sup>+</sup>CCR9<sup>+</sup> T and B cells in mice and humans<sup>6, 7</sup>. Moreover, RA, in the presence of TGF-β, potentiates the induction of Foxp3<sup>+</sup> regulatory T cells (T<sub>REG</sub>)<sup>8, 9</sup>, which are required for the establishment of OT<sup>2</sup>. We hypothesized that RA-dependent induction of gut-homing T cells is critically required for OT by promoting the differentiation of tolerogenic T<sub>REG</sub> in the gut lamina propria and by re-directing potentially pro-inflammatory T cells to the gut mucosa.

## Methods

### Mice

*Wt*, *β7*<sup>-/-</sup>, *Scurfy*, and *IL-10*<sup>-/-</sup> mice were purchased from Jackson Laboratories (Bar Harbor, ME). *CCR9*<sup>-/-</sup> and *LRAT*<sup>-/-</sup> mice have been described<sup>10, 11</sup>. DEREg mice<sup>12</sup> were provided by Dr. Thorsten Mempel (MGH, Boston). Experiments using *IL-10Rβ*<sup>-/-</sup> mice were done in collaboration with Dr. Scott Snapper (Children's Hospital, Boston). All mouse strains were used between 8–13 weeks of age. Mice were maintained in SPF/VAF animal facilities at MGH and used in accordance with the guidelines from the Subcommittee on Research Animal Care at MGH and HMS.

## OT induction

Mice were fed daily either 2.5 mg OVA or 0.25 mg MOG peptide (MOG<sub>35-55</sub>) via oral gavage for 5 days, as described<sup>3, 13</sup>.

## DTH

Mice were injected s.c. with 200  $\mu$ l OVA/CFA emulsion (250  $\mu$ g OVA plus 100  $\mu$ l CFA) in the tail base. Seven days later the mice were challenged with 50  $\mu$ l of aggregated OVA (10  $\mu$ g/ml) injected into the left footpad. The right footpad (control) received 50  $\mu$ l of PBS. The thickness of both hind footpads was measured 24 hours later with a caliper. Specific DTH was calculated as the difference between the left and the right footpad.

## Statistical analysis

Data are presented as mean  $\pm$  SEM and were analyzed using GraphPad Prism Software 5.0c (La Jolla, CA). Significance was determined using unpaired Student's t test or one-way ANOVA with Bonferroni's post-hoc tests, as appropriate.

## Results

### CCR9 is required for OT induction

To test the role of gut-homing lymphocytes in OT we used CCR9<sup>-/-</sup> mice, whose T cells are significantly impaired in their capacity to migrate to the small bowel<sup>6</sup>, we used the classical ovalbumin (OVA) skin DTH model as OT readout<sup>3, 13</sup>. If gut-homing is required for the establishment of OT we predicted that mice lacking CCR9 would develop DTH despite of being pre-treated orally with OVA. DTH was induced equally efficiently in *wt* and CCR9<sup>-/-</sup> mice that received oral PBS, indicating that CCR9 is not required for T cell recall responses or DTH induction. However, oral OVA administration prevented DTH responses only in *wt* mice, whereas CCR9<sup>-/-</sup> mice developed DTH regardless of whether they were pre-treated orally with OVA (Fig. 1A). Moreover, oral OVA did not decrease *ex vivo* OVA-specific cell proliferation in splenocytes from CCR9<sup>-/-</sup> mice, while it efficiently suppressed systemic recall responses in *wt* mice (Fig. 1B). As expected, polyclonal T cell activation induced similar levels of cell proliferation and IFN- $\gamma$  production in orally tolerized *wt* and CCR9<sup>-/-</sup> mice (Fig. S1). IL-10 is critical for OT<sup>14, 15</sup> and IL-4 seems to play a role in OT under some conditions<sup>15</sup>. Accordingly, systemic IL-10- and IL-4-producing cells were readily induced in *wt* mice, but not in CCR9<sup>-/-</sup> mice supplemented with oral OVA (Fig. 1C and Table S1). Reciprocally, the production of IL-2 and IFN- $\gamma$  was reduced in splenocytes from *wt* mice upon oral OVA administration, while it was not affected in CCR9<sup>-/-</sup> mice.

Similar to spleen, CD4<sup>+</sup> T cells isolated from draining popliteal PLN of orally tolerized *wt* but not CCR9<sup>-/-</sup> mice displayed lower OVA-specific proliferative responses and IFN- $\gamma$  production than CD4<sup>+</sup> T cells from mice given oral PBS (Fig. S2A, B), an effect that was mirrored by reduced cellularity in PLN of *wt* as compared to CCR9<sup>-/-</sup> mice (Fig. S2C). Moreover, increased IL-10 production was consistently observed at the protein and mRNA levels in OVA-stimulated CD4<sup>+</sup> T cells from PLN of orally tolerized *wt* but not CCR9<sup>-/-</sup> mice (Fig. S2D, E). Immunomodulation in OT also involves TGF- $\beta$ -producing cells<sup>16</sup>. Correspondingly, enhanced levels of *Tgfb1* mRNA were detected in CD4<sup>+</sup> T cells from PLN of orally tolerized *wt* but not CCR9<sup>-/-</sup> mice (Fig. S2F).

To extend our results to another OT experimental system we used the EAE model, in which OT can be generated by orally supplementing mice with a peptide derived from myelin oligodendrocyte glycoprotein (MOG<sub>35-55</sub>)<sup>1, 17</sup>. EAE developed similarly in *wt* and CCR9<sup>-/-</sup> mice supplemented orally with PBS (Fig. 1D), indicating that CCR9 is not required for EAE pathogenesis. However, orally administered MOG<sub>35-55</sub> prevented EAE only in *wt* but not in

CCR9<sup>-/-</sup> mice. Accordingly, cell proliferation upon *ex vivo* re-stimulation with MOG<sub>35-55</sub> was significantly reduced in splenocytes from MOG-tolerized *wt* mice, but not in cells from CCR9<sup>-/-</sup> mice (Fig. 1E). Th17 and Th1 cells are involved in EAE and DTH pathogenesis and OT induction abrogates the generation of these pro-inflammatory T cells<sup>18, 19</sup>. Consistently, MOG-tolerized *wt* mice showed lower frequencies of IL-17- and IFN- $\gamma$ -producing cells as compared to non-tolerized controls. However, CCR9<sup>-/-</sup> mice did not show a decrease in the proportions of Th17 or Th1 cells upon oral MOG<sub>35-55</sub> administration (Fig. S3). In summary, our results using two independent experimental systems indicate that CCR9 is critical for OT generation.

### Blocking MAdCAM-1 blocks migration of antigen-specific T cells to the gut and abrogates OT in *wt* mice

As a complementary approach we assessed the role of  $\alpha$ 4 $\beta$ 7-MAdCAM-1, the other gut-homing receptor pair<sup>6</sup>, in OT. Treatment of *wt* mice with a blocking mAb against MAdCAM-1 (clone MECA-367) increased the frequencies of systemic  $\alpha$ 4 $\beta$ 7<sup>+</sup> effector/memory CD4 T cells, an effect that was significantly more pronounced in mice that were orally supplemented with OVA (Fig. 2A, B), suggesting that oral OVA administration generated OVA-specific gut-homing CD4 T cells and that blocking  $\alpha$ 4 $\beta$ 7-MAdCAM-1 interaction prevented the migration of these cells to the gut, hence increasing their peripheral frequency. Given the low frequencies of endogenously generated OVA-specific CD4 T cells in OVA-tolerized mice, we could not reliably detect these cells in the small intestine lamina propria (LP). Nevertheless, adoptively transferred OT-II T cells (V $\beta$ 5.1<sup>+</sup>) were readily detected in the LP upon oral OVA supplementation (days 3 and 6) and they were markedly decreased by anti-MAdCAM-1 mAb (Fig. S4), indicating that OVA-specific T cells traffic to the small bowel LP upon activation in the MLN and that their homing to the LP is efficiently blocked by anti-MAdCAM-1 treatment.

Importantly, similar to CCR9<sup>-/-</sup> mice, anti-MAdCAM-1 mAb prevented OT in *wt* mice, as evidenced by increased skin DTH, higher *in vitro* OVA-specific proliferation, enhanced *ex vivo* IL-2 and IFN- $\gamma$  production, and lack of induction of systemic IL-10-producing cells as compared with mice treated with control rIgG (Fig. 2C–E). Thus, our data indicate that both gut-homing receptor pairs, CCR9-CCL25 and  $\alpha$ 4 $\beta$ 7-MAdCAM-1, are required for OT.

### OT is abolished in vitamin A depleted (VAD) mice

Since RA is required for imprinting gut-tropic  $\alpha$ 4 $\beta$ 7<sup>+</sup> CCR9<sup>+</sup> lymphocytes, we predicted that vitamin A-depleted (VAD) mice should be impaired in OT induction. For vitamin A depletion we used mice deficient in lecithin:retinol acyltransferase (LRAT<sup>-/-</sup>), which cannot store vitamin A in the liver and therefore can readily become VAD after only 2–3 weeks on a VAD diet, hence avoiding potential side effects of long-term vitamin A depletion<sup>10</sup>. DTH was similarly induced in mice on a control or VAD diet, indicating that RA is not required for recall T cell responses during DTH induction. However, OT was abrogated in VAD mice, as shown by increased skin DTH, higher *in vitro* OVA-specific proliferation and IL-2 production, and lack of systemic IL-10-producing cells when compared to mice on a control vitamin A-sufficient diet (Fig. 3A–C and Table S2). As expected, *ex vivo* polyclonal T cell activation induced similar levels of cell proliferation and IFN- $\gamma$  production in control and VAD mice (Fig. S5A). Of note, although RA has been shown to promote T<sub>REG</sub> differentiation<sup>8, 9</sup>, VAD mice exhibited only a mild decrease in T<sub>REG</sub> frequencies in MLN (Fig. S5B), which is in line with recent data indicating that VAD mice do not show a decrease in total T<sub>REG</sub><sup>20</sup>.

## Adoptive transfer of wt naïve T cells or gut-tropic T cells rescues OT in CCR9<sup>-/-</sup> and VAD mice, respectively

Next, we assessed which cell types need to express gut-homing receptors during OT induction. In addition to T cells, plasmacytoid DC (pDC) also play an important role in OT<sup>2, 13</sup>. Therefore, we explored whether wt T cells or pDC were sufficient to rescue OT in CCR9<sup>-/-</sup> mice. For this purpose, we adoptively transferred T cells or pDCs from non-tolerized wt or CCR9<sup>-/-</sup> donors into CCR9<sup>-/-</sup> recipient mice prior OT induction. Remarkably, adoptive transfer of wt T cells (CD45.1<sup>+</sup>) (Fig. S6A) was sufficient to fully restore OT in CCR9<sup>-/-</sup> mice, as indicated by reduced DTH responses, decreased *ex vivo* OVA-specific T cell proliferation and increased numbers of IL-10 producing cells upon oral OVA administration as compared to CCR9<sup>-/-</sup> mice adoptively transferred with a similar number of CCR9<sup>-/-</sup> T cells (Fig. 4A–C and Fig. S6B). Of note, transfer of  $\beta 7^{-/-}$  CCR9<sup>+/+</sup> T cells did not rescue OT in CCR9<sup>-/-</sup> mice (Fig. 4D and Fig. S6C), indicating that T cells need both CCR9 and  $\alpha 4\beta 7$  in order to rescue OT in CCR9<sup>-/-</sup> mice. On the other hand, adoptive transfer of wt pDC from BM was not sufficient to rescue OT in CCR9<sup>-/-</sup> mice (Fig. S6D, E).

We then asked whether adoptive transfer of T cells could also rescue OT in VAD mice. However, gut-homing induction is abrogated in mice lacking RA<sup>7, 21</sup>. Therefore, to bypass the lack of gut-homing imprinting in VAD mice, we generated gut-tropic T cells *ex vivo* by activating naïve CD4 T cells from Thy1.1<sup>+</sup> OT-II mice in the presence of RA<sup>7</sup>. Notably, *ex vivo*-generated gut-tropic OT-II CD4 T cells were sufficient to rescue OT induction in VAD mice (Fig. S7), suggesting that the most critical role of RA in OT is the induction of gut-tropic T cells, rather than other potential immune effects of RA, such as promoting T<sub>REG</sub> and IgA-ASC differentiation<sup>8, 9</sup>.

## Gut-homing receptors on T<sub>REG</sub> are required to rescue OT in CCR9<sup>-/-</sup> mice

We assessed the role of T<sub>REG</sub> in our experimental system. For depleting T<sub>REG</sub> we used DERE mice, which express diphtheria toxin (DT) receptor (DTR)-GFP under the control of the Foxp3 promoter. In line with previous work<sup>2, 3</sup>, T<sub>REG</sub> depletion in DT-treated DERE mice abrogated OT (Fig. S8A–C). As expected, DT treatment did not interfere with DTH or OT generation in wt (non-DERE) mice (Fig. S8B–C). Interestingly, despite that endogenous CCR9<sup>-/-</sup> T<sub>REG</sub> are found in CCR9<sup>-/-</sup> recipient mice (Fig. S8D), they were not sufficient for allowing OT induction in the absence of adoptively transferred wt T cells (Fig. 1), suggesting that T<sub>REG</sub> need to express CCR9 in order to allow for OT induction. Consistent with this possibility, specific depletion of CCR9<sup>+/+</sup> T<sub>REG</sub> derived from adoptively transferred DERE CD4 T cells abolished OT rescue in CCR9<sup>-/-</sup> mice (Fig. 4E, F and Fig. S8E). Analogous to CCR9<sup>-/-</sup> mice, OT was also abolished in  $\beta 7^{-/-}$  mice. Whereas wt CD4 T cells partially rescued OT in  $\beta 7^{-/-}$  mice, CD4 T cells from *Scurfy* mice, which lack functional Foxp3<sup>22</sup>, did not rescue OT in these mice (Fig. S9), confirming the key role of gut-tropic T<sub>REG</sub> in OT.

Previous reports suggested that naturally occurring thymus-derived T<sub>REG</sub> (nT<sub>REG</sub>) are not required for OT<sup>16</sup>, whereas adaptive/induced T<sub>REG</sub> (iT<sub>REG</sub>) play a critical role in OT generation<sup>23, 24</sup>. In line with these data, CD4 T cells from DERE mice depleted of nT<sub>REG</sub> rescued OT in CCR9<sup>-/-</sup> mice, whereas additional T<sub>REG</sub> depletion during oral OVA supplementation prevented OT rescue in CCR9<sup>-/-</sup> mice (Fig. S10). Thus, our data suggest that newly generated OVA-specific iT<sub>REG</sub> need to express CCR9 in order to generate OT.

## Gut-homing and IL-10 signaling are required for the generation of tolerogenic IL-10<sup>+</sup> T<sub>REG</sub>

T<sub>REG</sub><sup>2, 23, 25</sup> and IL-10 are critical for OT<sup>14, 15</sup>. Our results indicate that upon OT induction the production of IL-10 and TGF- $\beta 1$  is mostly confined to Foxp3<sup>+</sup>CD4<sup>+</sup> T<sub>REG</sub> (Fig. S11A).

Moreover, in agreement with a critical role of gut-homing during OT, anti-MAdCAM-1 treatment abrogated IL-10 production by T<sub>REG</sub> (Fig. S11B). In addition, adoptive transfer of naïve CD4 T cells from IL-10<sup>-/-</sup> mice failed to rescue OT and did not induce OVA-specific IL-10-producing cells in CCR9<sup>-/-</sup> mice upon oral OVA administration (Fig. 5A). Therefore, our data suggest that gut-tropic *wt* (IL-10<sup>+/+</sup>) CD4 T cells are required for the generation of IL-10<sup>+</sup> T<sub>REG</sub> in OT.

It has been proposed that IL-10 signaling is required on T<sub>REG</sub> to maintain their Foxp3 expression and suppressive function<sup>26, 27</sup>. Interestingly, similar to IL-10<sup>-/-</sup> T cells, adoptive transfer of CD4 T cells from IL-10Rβ<sup>-/-</sup> mice did not induce OVA-specific IL-10-producing cells in CCR9<sup>-/-</sup> mice upon oral OVA administration (Fig. 5B), suggesting that gut-homing CD4 T cells need to be exposed to IL-10 signals in the gut to become fully tolerogenic IL-10-producing cells in OT.

### Transfer of CCR9<sup>-/-</sup> or β7<sup>-/-</sup> T cells impairs OT in *wt* mice

Since oral antigen directs antigen-specific effector T cells to the gut mucosa by inducing α4β7 and CCR9<sup>6</sup>, we reasoned that, analogous to clonal deletion/anergy<sup>17</sup>, targeting T cells to the gut could be an alternative mechanism for excluding effector T cells from peripheral immune responses. Thus, we predicted that T cells deficient in gut-homing capacity might interfere with OT generation in *wt* mice. Consistent with this possibility, adoptive transfer of CCR9<sup>-/-</sup> or β7<sup>-/-</sup> T cells partially abrogated OT induction in *wt* mice, as determined by enhanced DTH responses and an increased OVA-specific T cell proliferation as compared with control *wt* mice (Fig. 6).

## Discussion

The prevailing view indicates that OT relies on the induction of antigen-specific T<sub>REG</sub> in the MLN, which then reach the blood and suppress pro-inflammatory responses in different tissues<sup>2, 3, 5, 23, 25, 28</sup>. However, although priming of naïve T cell in MLN is required for OT<sup>4, 5</sup>, our data indicate that T cell activation in MLN is not sufficient for OT induction. This is despite the fact that T<sub>REG</sub> are readily generated in MLN upon oral immunization and that MLN-DC are sufficient to induce T<sub>REG</sub> *ex vivo*<sup>9, 29, 30</sup>. We propose that T<sub>REG</sub> require a second activation step in the small intestine LP to complete their differentiation into fully tolerogenic IL-10-producing T<sub>REG</sub>, which can then suppress pro-inflammatory responses (Fig. 7). While the first step in MLN involves naïve T cells and therefore does not require gut-homing receptors, we propose that the second step in the small intestine LP depends on the induction of retinoic acid (RA)-dependent<sup>6</sup> gut-homing receptors α4β7 and CCR9 on differentiating T<sub>REG</sub>. Of note, homing to the gut is also required for further T<sub>REG</sub> expansion in the lamina propria<sup>24, 31</sup> and our results indicate that gut-homing induction might also target effector T cells to the intestinal mucosa, making them unavailable to participate in pro-inflammatory responses at peripheral sites.

IL-10<sup>14, 15, 31</sup> and TGF-β<sup>16</sup> are required for OT induction in different models. Given that the induction of systemic antigen-specific IL-10- and TGF-β-producing cells was markedly decreased in mice with impaired gut-homing, our data suggest that T cells need to migrate to the gut to become IL-10- and/or TGF-β-producing T<sub>REG</sub>. In fact, while intestinal T<sub>REG</sub> secrete IL-10, spleen T<sub>REG</sub> do not produce this critical tolerogenic cytokine<sup>32</sup>, which is consistent with our hypothesis of functional T<sub>REG</sub> specialization in the gut lamina propria in the setting of OT. Moreover, our results suggest that IL-10 signals on gut-tropic T<sub>REG</sub> are critical for promoting the differentiation of fully tolerogenic IL-10<sup>+</sup> T<sub>REG</sub> during OT. Among the possible sources for IL-10 in the LP are CX3CR1<sup>+</sup> macrophages<sup>24, 26</sup> and CD11b<sup>+</sup> DC<sup>33</sup>.

Of note, OT induction in an asthma model was recently correlated with the presence of a subset of CCR9<sup>+</sup> IL-10-producing T<sub>REG</sub> in the airways, leading to the speculation that CCR9 might be required for T<sub>REG</sub> homing to the airway mucosa upon OT induction<sup>31</sup>. However, since CCR9 has not been shown to play a role in lung homing, we propose that CCR9 expression on T<sub>REG</sub> in the asthma OT setting might reflect T<sub>REG</sub> priming in MLN by orally administered antigens and their subsequent differentiation in the small bowel LP into IL-10<sup>+</sup> T<sub>REG</sub>, which then migrate to the lung mucosa to suppress airway inflammation.

Interestingly, a subset of IL-10-producing cells has been specifically found among circulating memory CCR9<sup>+</sup> CD4 T cells in healthy human volunteers, whereas memory CCR9<sup>Neg</sup> CD4 T cells did not produce IL-10<sup>34</sup>, suggesting that human T cells might also need to express CCR9 in order to acquire tolerogenic IL-10-producing potential.

Other functions have been proposed for CCR9 in addition to gut-homing, such as effects on T cell apoptosis<sup>35</sup> and on T cell-epithelial cells interaction<sup>36</sup>. Nevertheless, since our data showed that the other gut-homing receptor pair  $\alpha$ 4 $\beta$ 7-MAdCAM-1 is also critical for OT induction, we favour the hypothesis that bona fide  $\alpha$ 4 $\beta$ 7- and CCR9-expressing gut-tropic T cells are required for OT. Moreover, given that the CCR9-CCL25 receptor pair plays a role only in small bowel homing<sup>6</sup>, especially in the upper segments<sup>37</sup>, we propose that T cell homing to the upper portions of the small bowel might be especially important for generating IL-10<sup>+</sup> T<sub>REG</sub> and OT. In agreement with this possibility, previous studies showed that antigen administration in the upper intestinal segments was more effective than inoculation in the ileum or colon for inducing OT<sup>38</sup>.

Even though RA promotes T<sub>REG</sub> induction *ex vivo*<sup>9, 29, 30</sup>, its *in vivo* role in T<sub>REG</sub> differentiation remains unclear. In fact, VAD mice did not show a decrease in T<sub>REG</sub> in MLN or the lamina propria<sup>20</sup>. Moreover, OT could be rescued in VAD mice by adoptively transferring exogenously generated gut-tropic antigen-specific CD4 T cells, suggesting that additional non gut-homing related roles for RA might not be essential during OT. Therefore, our data showing impaired OT in VAD are more likely explained by decreased gut-homing imprinting rather than by a direct effect on T<sub>REG</sub> generation, which is in line with our data in CCR9<sup>-/-</sup> mice or in *wt* mice after blocking MAdCAM-1.

Although adoptive transfer of spleen T<sub>REG</sub> from orally tolerized mice is sufficient to confer tolerance to naïve mice<sup>39</sup>, plasmacytoid DC (pDC) have also been proposed to play a key role in OT<sup>2, 13</sup> and adoptive transfer of pDC from orally tolerized mice was also sufficient to tolerize naïve mice in a DTH model<sup>13</sup>. In fact, a subset of immature pDC also expresses CCR9<sup>40</sup> and CCR9 plays a role in pDC homing to the gut<sup>41</sup>. However, in contrast to *wt* T cells, adoptive transfer of *wt* bone marrow CCR9<sup>+</sup> pDC was not sufficient to rescue OT in CCR9<sup>-/-</sup> mice. Nonetheless, it is formally possible that intravenously administered pDC did not home in sufficient numbers and/or to the proper tissue compartments.

In addition to active immunosuppression by T<sub>REG</sub> and clonal deletion/anergy<sup>17</sup>, our data suggest that induction of  $\alpha$ 4 $\beta$ 7CCR9<sup>+</sup> gut-tropic T cells is an alternative mechanism for OT by excluding effector, pro-inflammatory T cells from inducing potentially pathogenic immune responses at the peripheral sites. In fact, intestinal effector/memory T cells exhibit a very slow turnover and have a long dwell-time in the gut<sup>42</sup>, which might act like sequestering T cells. Conversely, interfering with gut-homing imprinting would allow effector T cells to remain in the periphery, potentially interfering with OT induction. Our experiments transferring T cells genetically deficient in gut-homing receptors emulate this scenario, as those cells are not targeted to the gut mucosa even when they are primed in gut-associated lymphoid compartments. Our findings might offer a partial explanation for the difficulty to mount tolerogenic responses during ongoing inflammatory responses as

compared to prophylactic tolerogenic treatments<sup>43</sup>. In this setting, peripherally primed T cells, induced in the context of extra-intestinal inflammation, would not acquire gut-homing receptors and therefore would not be efficiently targeted to and eventually retained in the gut mucosa.

In summary, our findings highlight a novel and unexpected link between gut-homing imprinting and mucosal immunological tolerance. In addition to establishing a novel role for gut-homing imprinting, our data suggest a need for caution when using immunotherapies aimed at blocking gut-homing receptors during chronic intestinal inflammation<sup>44</sup>, because of their potential to interfere with normal homeostatic regulatory mechanisms in the intestinal mucosa.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Susan Davis for editorial assistance. JRM is indebted to Ingrid Ramos for constant support.


**Funding:** BC was supported by an EMBO postdoctoral fellowship. EJV was supported by a postdoctoral fellowship from Crohn's & Colitis Foundation of America (CCFA). FJQ was supported by grants from NIH R00 AI075285-02, National Multiple Sclerosis Society (RG4111A1) and Boston Area Diabetes Endocrinology Research Center. HLW was supported by NIH grants AI435801 and NS38037. JRM was supported by grants from CCFA, Cancer Research Institute (CRI), Massachusetts Life Science Center (MLSC), NIH Pilot Feasibility Award P30 AR042689 and NIH New Director's Innovator Award DP2 2009A054301.

## References

1. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. *Nature*. 1995; 376:177–80. [PubMed: 7603570]
2. Dubois B, Joubert G, Gomez de Aguero M, Gouanvic M, Goubier A, Kaiserlian D. Sequential role of plasmacytoid dendritic cells and regulatory T cells in oral tolerance. *Gastroenterology*. 2009; 137:1019–28. [PubMed: 19345221]
3. Zhang X, Izikson L, Liu L, Weiner HL. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. *J Immunol*. 2001; 167:4245–53. [PubMed: 11591746]
4. Spahn TW, Weiner HL, Rennert PD, Luger N, Fontana A, Domschke W, Kucharzik T. Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. *Eur J Immunol*. 2002; 32:1109–13. [PubMed: 11920578]
5. Worbs T, Bode U, Yan S, Hoffmann MW, Hintzen G, Bernhardt G, Forster R, Pabst O. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. *J Exp Med*. 2006; 203:519–27. [PubMed: 16533884]
6. Mora JR. Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids. *Inflamm Bowel Dis*. 2008; 14:275–89. [PubMed: 17924560]
7. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. *Immunity*. 2004; 21:527–38. [PubMed: 15485630]
8. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science*. 2007; 317:256–60. [PubMed: 17569825]
9. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. *J Exp Med*. 2007; 204:1775–1785. [PubMed: 17620362]
10. O'Byrne SM, Wongsiriroj N, Libien J, Vogel S, Goldberg IJ, Baehr W, Palczewski K, Blaner WS. Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT). *J Biol Chem*. 2005; 280:35647–57. [PubMed: 16115871]


11. Uehara S, Grinberg A, Farber JM, Love PE. A role for CCR9 in T lymphocyte development and migration. *J. Immunol.* 2002; 168:2811–2819. [PubMed: 11884450]
12. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, Hamann A, Wagner H, Huehn J, Sparwasser T. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. *J Exp Med.* 2007; 204:57–63. [PubMed: 17200412]
13. Goubier A, Dubois B, Gheit H, Joubert G, Villard-Truc F, Asselin-Paturel C, Trinchieri G, Kaiserlian D. Plasmacytoid dendritic cells mediate oral tolerance. *Immunity.* 2008; 29:464–75. [PubMed: 18789731]
14. Cong Y, Liu C, Weaver CT, Elson CO. Early upregulation of T cell IL-10 production plays an important role in oral tolerance induction. *Ann N Y Acad Sci.* 2004; 1029:319–20. [PubMed: 15681770]
15. Rizzo LV, Morawetz RA, Miller-Rivero NE, Choi R, Wiggert B, Chan CC, Morse HC 3rd, Nussenblatt RB, Caspi RR. IL-4 and IL-10 are both required for the induction of oral tolerance. *J Immunol.* 1999; 162:2613–22. [PubMed: 10072503]
16. Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille JJ, Curotto de Lafaille MA. Oral tolerance in the absence of naturally occurring Tregs. *J Clin Invest.* 2005; 115:1923–33. [PubMed: 15937545]
17. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. *Science.* 1994; 265:1237–40. [PubMed: 7520605]
18. Peron JP, Yang K, Chen ML, Brandao WN, Basso AS, Commodaro AG, Weiner HL, Rizzo LV. Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice. *J Neuroimmunol.* 2010; 227:10–7. [PubMed: 20580440]
19. Arnaboldi PM, Roth-Walter F, Mayer L. Suppression of Th1 and Th17, but not Th2, responses in a CD8(+) T cell-mediated model of oral tolerance. *Mucosal Immunol.* 2009; 2:427–38. [PubMed: 19571798]
20. Cha HR, Chang SY, Chang JH, Kim JO, Yang JY, Kim CH, Kweon MN. Downregulation of Th17 cells in the small intestine by disruption of gut flora in the absence of retinoic acid. *J Immunol.* 2010; 184:6799–806. [PubMed: 20488794]
21. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, Otipoby KL, Yokota A, Takeuchi H, Ricciardi-Castagnoli P, Rajewsky K, Adams DH, von Andrian UH. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. *Science.* 2006; 314:1157–60. [PubMed: 17110582]
22. Brunkow ME, Jeffery EW, Hjerrild KA, Paepfer B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nature genetics.* 2001; 27:68–73. [PubMed: 11138001]
23. Curotto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, Lafaille JJ. Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. *Immunity.* 2008; 29:114–26. [PubMed: 18617425]
24. Hadis U, Wahl B, Schulz O, Hardtke-Wolenski M, Schippers A, Wagner N, Muller W, Sparwasser T, Forster R, Pabst O. Intestinal Tolerance Requires Gut Homing and Expansion of FoxP3(+) Regulatory T Cells in the Lamina Propria. *Immunity.* 2011; 34:237–46. [PubMed: 21333554]
25. Hauet-Broere F, Unger WW, Garssen J, Hoijsen MA, Kraal G, Samsom JN. Functional CD25- and CD25+ mucosal regulatory T cells are induced in gut-draining lymphoid tissue within 48 h after oral antigen application. *Eur J Immunol.* 2003; 33:2801–10. [PubMed: 14515264]
26. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. *Nature immunology.* 2009; 10:1178–84. [PubMed: 19783988]
27. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Bruning JC, Muller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. *Immunity.* 2011; 34:566–78. [PubMed: 21511185]

28. Ferguson A, Mowat AM, Strobel S, Barnetson RS. T-cell mediated immunity in food allergy. *Annals of allergy*. 1983; 51:246–8. [PubMed: 6603801]
29. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF- $\beta$ - and retinoic acid-dependent mechanism. *J Exp Med*. 2007; 204:1757–1764. [PubMed: 17620361]
30. Benson MJ, Pino-Lagos K, Roseblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. *J Exp Med*. 2007:1775–1774. [PubMed: 17620362]
31. Navarro S, Cossalter G, Chiavaroli C, Kanda A, Fleury S, Lazzari A, Cazareth J, Sparwasser T, Dombrowicz D, Glaichenhaus N, Julia V. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. *Mucosal Immunol*. 2011; 4:53–65. [PubMed: 20811345]
32. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, Fontenot JD, Ramsdell F, Powrie F. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. *Journal of immunology*. 2006; 177:5852–60.
33. Liu B, Tonkonogy SL, Sartor RB. Antigen-Presenting Cell Production of IL-10 Inhibits T-Helper 1 and 17 Cell Responses and Suppresses Colitis in Mice. *Gastroenterology*. 2011
34. Papadakis KA, Landers C, Prehn J, Kouroumalis EA, Moreno ST, Gutierrez-Ramos JC, Hodge MR, Targan SR. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. *J Immunol*. 2003; 171:159–65. [PubMed: 12816994]
35. Youn BS, Kim YJ, Mantel C, Yu KY, Broxmeyer HE. Blocking of c-FLIP(L)--independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. *Blood*. 2001; 98:925–33. [PubMed: 11493434]
36. Ericsson A, Svensson M, Arya A, Agace WW. CCL25/CCR9 promotes the induction and function of CD103 on intestinal intraepithelial lymphocytes. *Eur J Immunol*. 2004; 34:2720–9. [PubMed: 15368288]
37. Stenstad H, Svensson M, Cucak H, Kotarsky K, Agace WW. Differential homing mechanisms regulate regionalized effector CD8 $\alpha$  T cell accumulation within the small intestine. *Proc Natl Acad Sci U S A*. 2007; 104:10122–7. [PubMed: 17551016]
38. Wakabayashi A, Kumagai Y, Watari E, Shimizu M, Utsuyama M, Hirokawa K, Takahashi H. Importance of gastrointestinal ingestion and macromolecular antigens in the vein for oral tolerance induction. *Immunology*. 2006; 119:167–77. [PubMed: 16796692]
39. Faria AM, Weiner HL. Oral tolerance. *Immunol Rev*. 2005; 206:232–59. [PubMed: 16048553]
40. Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. *Nat Immunol*. 2008; 9:1253–60. [PubMed: 18836452]
41. Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, Pabst O, Forster R. CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. *Proc Natl Acad Sci U S A*. 2007; 104:6347–52. [PubMed: 17404233]
42. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrancois L. Dynamics of blood-borne CD8 memory T cell migration in vivo. *Immunity*. 2004; 20:551–562. [PubMed: 15142524]
43. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. *Immunological reviews*. 2011; 241:241–59. [PubMed: 21488901]
44. Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. *Inflamm Bowel Dis*. 2008; 14:1298–312. [PubMed: 18393377]




### Figure 1. CCR9 is required for OT induction

(A–C) Wild type (*wt*) and CCR9<sup>-/-</sup> mice were supplemented daily with oral PBS or 2.5 mg OVA for 5 days, and then they were immunized s.c. with OVA plus CFA. After 7 days the mice were challenged with OVA in the left footpad and PBS in the right footpad. (A) DTH responses were measured after 24 hours (n=7–9 mice/group). (B, C) Total splenocytes were stimulated with 1 mg/ml OVA. (B) Cell proliferation was assessed after 72 hours. (C) Cytokines were measured in the culture supernatant after 24–48 hours. (D, E) *Wt* and CCR9<sup>-/-</sup> mice were supplemented daily with oral PBS or 0.25 mg MOG<sub>35–55</sub> for 5 days, then immunized s.c. with MOG<sub>35–55</sub> plus CFA. (D) EAE induction and progression was scored from days 11 to 25 (n=8–10 mice/group). (E) At day 16, the mice were sacrificed and total splenocytes were stimulated *ex vivo* with 20 μg/ml MOG<sub>35–55</sub>. T cell proliferation was measured after 72 hours (n=4 mice/group). Mean ± SEM, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, n.s.: not significant.




### Figure 2. Blocking MAdCAM-1 abrogates OT in *wt* mice

*Wt* mice were treated i.p. with anti-MAdCAM-1 or control rIgG. OT and DTH were induced as described in Fig. 1. (A) Flow cytometry analysis of one representative mouse/group. (B) Frequencies of  $\alpha 4\beta 7$ - and CCR9-expressing cells in the spleen. Cells were gated on CD44<sup>Hi</sup>CD62L<sup>Low</sup> effector/memory CD4<sup>+</sup> T cells (C) DTH responses were measured after 24 hours (n=2–3 mice/group). (D, E) Total splenocytes were stimulated with the indicated OVA concentrations. (D) Proliferation was measured after 72 hours (n=2–3 mice/group). (E) Cytokines were measured in the culture supernatant after 24–48 hours. Mean  $\pm$  SEM, \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, n.s.: not significant.




**Figure 3. OT is abolished in vitamin A depleted (VAD) mice**

Mice were maintained on a control or VAD diet. OT and DTH were induced as described in Fig. 1. (A) DTH responses (footpad swelling) were measured after 24 hours, and were expressed as the difference between the left and right footpad (L-R) (n=4 mice/group). (B, C) Total splenocytes were stimulated with 1 mg/ml OVA. (B) T cell proliferation was measured after 72 hours. (C) Cytokines were measured in the culture supernatant after 24–48 hours. Mean  $\pm$  SEM, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, n.s.: not significant.




#### Figure 4. Adoptive transfer of *wt* T cells rescues OT in *CCR9*<sup>-/-</sup> mice

T cells from nontolerized *wt* or *CCR9*<sup>-/-</sup> mice were adoptively transferred into *CCR9*<sup>-/-</sup> recipients. OT and DTH were induced as described in Fig. 1. *CCR9*<sup>-/-</sup> mice receiving CD4<sup>+</sup> T cells from DEREK mice were treated with DT every day. (A, E) DTH responses were measured after 24 hours (n=2–5 mice/group). (B–D, F) Total splenocytes were stimulated with the indicated OVA concentrations. (B, D, F) Proliferation was assessed after 72 hours (n=4–5 mice/group). (C) IL-10 was measured in the culture supernatant after 48–60 hours. Mean ± SEM, \*p<0.05, \*\*\*p<0.001




### Figure 5. IL-10 signals in gut-tropic TREG are critical for OT

T cells from IL-10<sup>-/-</sup> or IL-10Rβ<sup>-/-</sup> mice were adoptively transferred into CCR9<sup>-/-</sup> mice. OT and DTH were induced as described in Fig. 1. (A) Total splenocytes were stimulated with the indicated OVA concentrations and cell proliferation was measured after 72 h. (B, C) Cytokines were measured in the culture supernatant after 48–60 hours. n=2 mice/group, Mean ± range



**Figure 6. Transfer of CCR9<sup>-/-</sup> or β7<sup>-/-</sup> T cells impairs OT in wt mice**

T cells from CCR9<sup>-/-</sup> or β7<sup>-/-</sup> mice were adoptively transferred into wt mice. OT and DTH were induced as described in Fig. 1. (A) DTH responses were measured after 24h (n= 2 mice/group). Groups were compared versus wild type mice receiving oral PBS. (B) Total splenocytes were stimulated with the indicated OVA concentrations and cell proliferation was measured after 72h (n= 2 mice/group). Mean ± SEM, \*p<0.05 (ANOVA)



**Figure 7. Gut-homing-dependent model for OT**

(A) The prevailing view indicates that OT relies on the induction of antigen-specific Foxp3<sup>+</sup> regulatory T cells (T<sub>REG</sub>) in the mesenteric lymph nodes (MLN), which then reach the blood and suppress pro-inflammatory responses in different tissues. (B) In our new model we propose that T<sub>REG</sub> require a second activation step in the intestinal lamina propria (LP) to complete their differentiation into fully tolerogenic IL-10-producing T<sub>REG</sub>, which can then suppress pro-inflammatory responses. While the first step in MLN involves naïve T cells and therefore does not require gut-homing receptors, the second step in the gut LP depends on the induction of retinoic acid (RA)-dependent gut-homing receptors  $\alpha 4\beta 7$  and CCR9 on activated T<sub>REG</sub> and their respective ligands MAdCAM-1 and CCL25 on LP endothelial cells. In the LP T<sub>REG</sub> are re-stimulated and proliferate in response to oral antigen and they are also exposed to IL-10, which is required to confer T<sub>REG</sub> with IL-10-producing capacity, a critical property for OT generation. After that, IL-10<sup>+</sup> T<sub>REG</sub> return to the blood and exert their tolerogenic activity in different organs.